Total Payments
$428,161
2024 Payments
$3,150
Companies
6
Transactions
37
Medicare Patients
2,162
Medicare Billing
$136,946
Payment Breakdown by Category
Research$398,550 (93.1%)
Consulting$25,740 (6.0%)
Other$3,750 (0.9%)
Food & Beverage$120.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $398,550 | 30 | 93.1% |
| Consulting Fee | $25,740 | 2 | 6.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,750 | 4 | 0.9% |
| Food and Beverage | $120.80 | 1 | 0.0% |
Payments by Type
Research
$398,550
30 transactions
General
$29,611
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $395,400 | 29 | $0 (2023) |
| Perspectum Diagnostics Ltd | $24,900 | 1 | $0 (2023) |
| BOSTON SCIENTIFIC CORPORATION | $3,750 | 4 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $3,150 | 1 | $0 (2024) |
| PFIZER INC. | $840.00 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $120.80 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,150 | 1 | Regeneron Pharmaceuticals, Inc. ($3,150) |
| 2023 | $208,500 | 14 | Novo Nordisk AS ($183,600) |
| 2022 | $162,300 | 11 | Novo Nordisk AS ($162,300) |
| 2021 | $53,250 | 9 | Novo Nordisk AS ($49,500) |
| 2019 | $840.00 | 1 | PFIZER INC. ($840.00) |
| 2018 | $120.80 | 1 | E.R. Squibb & Sons, L.L.C. ($120.80) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/07/2024 | Regeneron Pharmaceuticals, Inc. | — | — | Cash or cash equivalent | $3,150.00 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 12/14/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $21,600.00 | Research |
| Study: NN9931-4553 | ||||||
| 12/08/2023 | Perspectum Diagnostics Ltd | LiverMultiScan (Device) | Consulting Fee | Cash or cash equivalent | $24,900.00 | General |
| Category: Radiology | ||||||
| 11/09/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $9,900.00 | Research |
| Study: NN9931-4553 | ||||||
| 10/13/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $21,600.00 | Research |
| Study: NN9931-4553 | ||||||
| 09/26/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $24,600.00 | Research |
| Study: NN9931-4553 | ||||||
| 08/23/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $10,500.00 | Research |
| Study: NN9931-4553 | ||||||
| 07/20/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $9,900.00 | Research |
| Study: NN9931-4553 | ||||||
| 06/28/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $6,000.00 | Research |
| Study: NN9931-4553 | ||||||
| 06/16/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $9,300.00 | Research |
| Study: NN9931-4553 | ||||||
| 05/24/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $17,100.00 | Research |
| Study: NN9931-4553 | ||||||
| 04/20/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $16,800.00 | Research |
| Study: NN9931-4553 | ||||||
| 04/13/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $11,400.00 | Research |
| Study: NN9931-4553 | ||||||
| 02/16/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $12,600.00 | Research |
| Study: NN9931-4553 | ||||||
| 01/20/2023 | Novo Nordisk AS | — | — | Cash or cash equivalent | $12,300.00 | Research |
| Study: NN9931-4553 | ||||||
| 12/16/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $6,900.00 | Research |
| Study: NN9931-4553 | ||||||
| 12/02/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $15,900.00 | Research |
| Study: NN9931-4553 | ||||||
| 10/20/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $13,500.00 | Research |
| Study: NN9931-4553 | ||||||
| 09/22/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $10,800.00 | Research |
| Study: NN9931-4553 | ||||||
| 08/18/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $16,500.00 | Research |
| Study: NN9931-4553 | ||||||
| 07/21/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $16,500.00 | Research |
| Study: NN9931-4553 | ||||||
| 06/09/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $15,000.00 | Research |
| Study: NN9931-4553 | ||||||
| 05/25/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $15,600.00 | Research |
| Study: NN9931-4553 | ||||||
| 05/19/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $21,600.00 | Research |
| Study: NN9931-4553 | ||||||
| 02/17/2022 | Novo Nordisk AS | — | — | Cash or cash equivalent | $15,300.00 | Research |
| Study: NN9931-4553 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9931-4553 | Novo Nordisk AS | $395,400 | 29 |
| A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | Regeneron Pharmaceuticals, Inc. | $3,150 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 9 | 579 | 965 | $131,000 | $32,891 |
| 2021 | 10 | 725 | 1,318 | $180,275 | $48,064 |
| 2020 | 10 | 858 | 1,549 | $211,140 | $55,990 |
Total Patients
2,162
Total Services
3,832
Medicare Billing
$136,946
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2022 | 230 | 440 | $52,635 | $13,115 | 24.9% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2022 | 61 | 68 | $17,899 | $4,800 | 26.8% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Facility | 2022 | 55 | 56 | $15,048 | $4,017 | 26.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 75 | 145 | $17,419 | $3,657 | 21.0% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2022 | 20 | 22 | $10,190 | $2,632 | 25.8% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2022 | 26 | 90 | $8,088 | $2,114 | 26.1% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2022 | 38 | 44 | $4,876 | $1,289 | 26.4% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2022 | 21 | 23 | $1,944 | $498.73 | 25.7% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2022 | 22 | 43 | $1,654 | $444.58 | 26.9% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2022 | 31 | 34 | $1,247 | $323.62 | 25.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2021 | 301 | 669 | $79,064 | $20,728 | 26.2% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2021 | 87 | 113 | $29,487 | $8,163 | 27.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2021 | 74 | 170 | $20,071 | $5,483 | 27.3% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Facility | 2021 | 58 | 58 | $16,189 | $4,099 | 25.3% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2021 | 27 | 29 | $13,328 | $3,716 | 27.9% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2021 | 25 | 75 | $6,705 | $1,803 | 26.9% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2021 | 39 | 44 | $4,866 | $1,269 | 26.1% |
| 88331 | Pathology examination of specimen during surgery, first tissue block | Facility | 2021 | 12 | 21 | $4,126 | $1,036 | 25.1% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2021 | 34 | 65 | $2,483 | $685.75 | 27.6% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2021 | 24 | 27 | $2,265 | $629.37 | 27.8% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2021 | 44 | 47 | $1,692 | $451.79 | 26.7% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2020 | 397 | 886 | $105,678 | $26,954 | 25.5% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2020 | 76 | 92 | $24,115 | $6,807 | 28.2% |
| 88321 | Surgical pathology consultation and report | Facility | 2020 | 80 | 80 | $22,777 | $5,932 | 26.0% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2020 | 25 | 29 | $13,417 | $3,846 | 28.7% |
About Dr. Meng-Che Yeh, MD
Dr. Meng-Che Yeh, MD is a Anatomic Pathology & Clinical Pathology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1104983642.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Meng-Che Yeh, MD has received a total of $428,161 in payments from pharmaceutical and medical device companies, with $3,150 received in 2024. These payments were reported across 37 transactions from 6 companies. The most common payment nature is "" ($398,550).
As a Medicare-enrolled provider, Yeh has provided services to 2,162 Medicare beneficiaries, totaling 3,832 services with total Medicare billing of $136,946. Data is available for 3 years (2020–2022), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Anatomic Pathology & Clinical Pathology
- Location Seattle, WA
- Active Since 01/03/2007
- Last Updated 10/21/2011
- Taxonomy Code 207ZP0102X
- Entity Type Individual
- NPI Number 1104983642
Products in Payments
- LiverMultiScan (Device) $24,900
- EXALT (Device) $1,875
- SPYGLASS (Device) $1,875
- OPDIVO (Biological) $120.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anatomic Pathology & Clinical Pathology Doctors in Seattle
Charles Alpers
Anatomic Pathology & Clinical Pathology — Payments: $114,121
Anatomic Pathology & Clinical Pathology $114,121
Eric Konnick, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $45,062
Anatomic Pathology & Clinical Pathology $45,062
Dr. Ryan Metcalf, M.d, M.D
Anatomic Pathology & Clinical Pathology — Payments: $37,636
Anatomic Pathology & Clinical Pathology $37,636
Howard Shulman
Anatomic Pathology & Clinical Pathology — Payments: $22,639
Anatomic Pathology & Clinical Pathology $22,639
Erin Rudzinski, Md, MD
Anatomic Pathology & Clinical Pathology — Payments: $16,144
Anatomic Pathology & Clinical Pathology $16,144
Jing Zhang
Anatomic Pathology & Clinical Pathology — Payments: $10,240
Anatomic Pathology & Clinical Pathology $10,240